Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mauna Kea Technologies Takes Confocal Microscopy to the Tissues: An Interview with Sacha Loiseau

Executive Summary

Originally a tool for biologists, confocal microscopy provides high resolution in vivo imaging of cellular and subcellular tissue structures in real time. As a clinical solution, the technology is meant to help bridge the gap between more imprecise macroscopic imaging technologies (such as MRI, CT, PET, high-resolution ultrasound, etc.) and microscopic techniques used in the clinical laboratory. Medtech Insight talks with Sacha Loiseau, PhD, president and CEO of Mauna Kea Technologies, a French medical device firm that recently launched its Cellvizio platform, an advanced confocal laser microscopy system with ultra-thin fiber optic microprobes.

You may also be interested in...



Innovation Fuels Growth In GI Endoscopy

Advances in imaging and interventional endoscopy are improving cancer detection and enabling less invasive approaches to diagnose and treat disorders in the gastrointestinal tract. These emerging procedures are poised to fuel growth in the $7 billion global market for GI endoscopy.

A Bright Future For Optical Imaging

One bright spot emerging in this otherwise lackluster economy is the market for optical imaging technologies. Optical imaging encompasses a wide array of current and emerging techniques that use light as the primary imaging modality to characterize local anatomy down to cellular and molecular levels.

NinePoint Medical Inc.

Over the past 20 years, the diagnosis of esophageal adenocarcinoma - the most common form of esophageal cancer - has doubled in the US and now stands at roughly 16,500 new cases each year. This dramatic increase is believed to be related to an increased incidence of gastroesophageal reflux disease (GERD) and obesity. Physicians agree that to slow the increase in this deadly cancer, detection at its earliest stages is critical. Unfortunately, the standard tools available to do this are less than ideal. NinePoint Medical has developed technology designed to detect precursors to esophageal cancer in real time, in vivo, using near-infrared light and complex computing algorithms.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel